Paediatric Strategy Forum for Medicinal Product Development of Checkpoint inhibitors for use in combination therapy in paediatric patients

5 & 6 September 2018

Draft programme

- Introduction
- Immunological environment of paediatric malignancy
- Development of checkpoint inhibitors in adults with lessons relevant to paediatrics
- Checkpoint inhibitors in early phase clinical studies *
- Checkpoint inhibitors - Biallelic mismatch repair, MSI status and tumour burden as potential predictive biomarkers
- Strategies combining checkpoint inhibitors with other products*
- Alternative immunotherapy strategies *
- Strategic discussion
- Conclusions

* Presentations from the pharmaceutical industry in these sessions